Cycle on Jun 26, 2026

I will start by listing the active threads for this topic to understand what questions are open and if there are any watches or specific investigations currently pending.

I will search the web for the latest major health and science news, clinical trial readouts, and FDA decisions from the past week to see what has occurred or changed.

The search has returned several fascinating results from the past few days: 1. "FDA pilot program aims to speed up early-stage clinical trials" - STAT reported on June 22, 2026. This looks closely related to the "Operation Trailblazer" initiative that was launched by HHS and FDA on June 22, 2026. Let's research this further. 2. "Capricor thrown for another loop as FDA sets adcomm for DMD cardiomyopathy therapy" - Published on June 26, 2026. Capricor's deramiocel (formerly CAP-1002) for DMD cardiomyopathy. 3. "Replimune gets early August decision date for twice-rejected melanoma drug" - Replimune's RP1 for melanoma has an early August decision date. 4. "PharmaEssentia Announces FDA Approval and U.S. Launch of BESREMi Pen™ (ropeginterferon alfa-2b-njft) for Polycythemia Vera" on June 26, 2026. 5. "Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer" on June 26, 2026. Datroway is datopotamab deruxtecan (Dato-DXd). Let's check this out. Let's run a web search to drill down on the FDA pilot program details and Operation Trailblazer. I also want to search for other major clinical trial readouts, FDA approvals, or public health news over the last 5-7 days. Let's do a search on "Operation Trailblazer" and "FDA pilot program".

Excellent. Let's fetch some of these pages to get details about Operation Trailblazer and the FDA's new actions/draft guidance, which directly updates the prior finding `hhs-clinical-trials-reform-operation-trialblazer`. Let's first fetch the HHS official press release or the RAPS article. Let's use `web_fetch` on: 1. `https://www.hhs.gov/press-room/hhs-launches-clinical-trials-reform-initiative.html` 2. `https://www.raps.org/resource/hhs-and-fda-propose-clinical-trial-reforms-to-expedite-drug-development.html` 3. `https://thehill.com/policy/healthcare/5934886-us-china-clinical-trial-competition/` Let's do this one by one or in parallel. I will start by fetching the HHS press release first.

This is an excellent primary source. It describes: 1. The FDA soliciting public comments on a "pilot program" to shorten timelines for first-in-human Phase 1 clinical trials, and clarifying regulatory expectations that could reduce early trial timelines by 6 to 12 months. 2. Draft guidance clarifying that a single high-quality late-stage clinical trial with confirmatory evidence will generally be sufficient for drug approval. 3. NIH, NCATS, NCI, ONC, ARPA-H (THRIVE, CATALYST programs), and HHS OIG (RFI on safe harbor regulations under the Federal anti-kickback statute or exceptions to civil monetary penalties for clinical trial incentives) roles. Let's fetch the RAPS article to get more granular details, particularly about the FDA's draft guidance and pilot program. This will allow us to expand and refine our existing note `hhs-clinical-trials-reform-operation-trialblazer`. Let's fetch `https://www.raps.org/resource/hhs-and-fda-propose-clinical-trial-reforms-to-expedite-drug-development.html`.

This is extremely detailed and provides high-value specifics for updating `hhs-clinical-trials-reform-operation-trialblazer`! Key points to include: - The Expedited Investigational New Drug (IND) pilot program: qualified external institutions (like academic medical centers or CROs) collaborate with sponsors to develop and review protocols for FIH clinical trials using a rolling IND submission platform to minimize clinical holds. Public docket open for comment until July 22, 2026. - Revised draft guidance: "Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products," clarifying when developers can rely on just one rigorous pivotal trial plus confirmatory evidence. Comments due August 24, 2026. - Draft guidance on Quantitative Systems Pharmacology (QSP)-based dose selection to determine the Minimum Anticipated Biological Effect Level (MABEL) dose in FIH Phase 1 trials, moving away from historical methods based on animal toxicology studies. Comments due July 24, 2026. - Updated draft guidance on master protocols, including basket, umbrella, and platform trials. - Launch of "The Phase 1 IND Navigator" webpage. - New webpage on Chemistry, Manufacturing, and Control (CMC) information clarifying phase-specific requirements for Phase 1 INDs to prevent companies from submitting unnecessary data. - A new call center for Phase 1 trials (240-276-9358 or Phase1Questions@fda.hhs.gov) for real-time answers. This is a comprehensive update to `hhs-clinical-trials-reform-operation-trialblazer`. Now let's check other major updates. Let's see what is happening with clinical trial readouts or FDA approvals. Let's do a search on: - Capricor deramiocel (CAP-1002) FDA adcomm. - Replimune RP1 melanoma FDA decision. - CHMP recommendation of Datroway (datopotamab deruxtecan) in TNBC. - PharmaEssentia BESREMi Pen FDA approval. - Any other major trials, space, energy, or disease outbreaks. Let's search on "bird flu" or "H5N1" and "vaccine" or "outbreak". Let's also check on ISS Russian Zvezda module air leaks or other space/energy news. Let's do a search on Capricor deramiocel.

Let's fetch `https://www.biospace.com/fda/capricor-thrown-for-another-loop-as-fda-sets-adcomm-for-dmd-cardiomyopathy-therapy` to read the full story. This is a highly relevant regulatory event under our brief of consequential science and health. Let's fetch it.

This is a fantastic article detailing the current state of Capricor's deramiocel, the FDA's resubmission review, and the announcement of an upcoming advisory committee meeting on July 29, 2026. It also mentions Replimune's RP1 for advanced melanoma getting an adcomm date ahead of its August 2, 2026 decision date. Let's see if we can find more about Replimune's RP1. Let's do a web search on: - "Replimune" "RP1" FDA advisory committee Let's search for this.

Let's fetch `https://www.biospace.com/fda/replimune-gives-cancer-immunotherapy-a-third-try-after-fda-leadership-shakeup` to read about Replimune's RP1. This is a very interesting regulatory development that highlights the post-Makary/Prasad FDA landscape. Let's fetch it.

These two articles together paint an incredibly cohesive picture of a significant shift in FDA regulatory dynamics following the departures of former FDA Commissioner Marty Makary and CBER director Vinay Prasad. Let's review what's happening: - Capricor's deramiocel (CAP-1002) for DMD cardiomyopathy was previously rejected in July 2025. It aced its Phase 3 HOPE-3 trial in December 2025, and the resubmitted BLA was accepted in March 2026 with an August 22, 2026 PDUFA date. Now, the FDA has scheduled an advisory committee meeting (Cellular, Tissue, and Gene Therapies Advisory Committee) for July 29, 2026. - Replimune's RP1 for advanced melanoma was rejected twice (July 2025 and April 2026). Following the departure of FDA Commissioner Marty Makary, the FDA and Replimune aligned on a path forward. Replimune resubmitted the BLA (which the FDA accepted on June 26, 2026) with a PDUFA target date of August 2, 2026, and the FDA plans to hold an advisory committee meeting in late July. - These events are widely viewed by industry observers as a "return to normalcy" and a pivot toward more structured, public advisory committees (adcomms) after a period of high-profile, unilateral rejections and regulatory friction under the previous FDA leadership. Let's search for other major clinical trial readouts, FDA approvals, or public health news over the last week. Let's do a search on: - CHMP recommendation of Datroway (datopotamab deruxtecan) in TNBC. Let's see what is Datroway and the CHMP recommendation. - Besremi Pen FDA approval. - Is there any news on other active watches? Let's check: - Amgen Tavneos FDA hearing submission and public docket close (June 29, 2026). Let's search "Amgen Tavneos" or "Tavneos" FDA. - uniQure BLA submission for AMT-130 in Huntington's disease. - MoonLake sonelokimab. - ISS Russian Zvezda module air leaks. - H5N1 bird flu vaccine clinical trial or outbreak updates. Let's search "H5N1" "vaccine" "Phase 3" or other H5N1 updates. Let's search "bird flu" vaccine. Let's do a search for CHMP recommendation of Datroway first.

Let's fetch `https://www.astrazeneca.com/media-centre/press-releases/2026/datroway-recommended-for-approval-in-eu-for-tnbc.html` to get the specifics of the TROPION-Breast02 trial and the CHMP positive opinion. This is a major regulatory event for an antibody-drug conjugate (ADC). Let's fetch it.

This is another high-impact regulatory update: - AstraZeneca and Daiichi Sankyo's Datroway (datopotamab deruxtecan; Dato-DXd) received a positive opinion from the CHMP in the EU as first-line monotherapy for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitors. - This is based on the Phase III TROPION-Breast02 trial, which showed a statistically significant 5.0-month improvement in median overall survival (OS) compared to chemotherapy (23.7 months vs 18.7 months, HR 0.79, p=0.0291) and a 43% reduction in risk of disease progression or death (HR 0.57, p<0.0001). - Datroway was already approved in the US in May 2026 for this indication. If approved in the EU, it could be the first TROP2-directed ADC in the EU with a demonstrated OS benefit in the first-line setting. Let's check if there is any update on "Amgen Tavneos FDA hearing" or "Tavneos" (PDUFA or FDA hearing). The watch `019ec855-5381-7936-a3b6-a40d207e679d` is: "Monitor Amgen's submission of the Duke Clinical Research Institute (DCRI) independent re-evaluation of the ADVOCATE trial data and the close of the FDA public comment period on the proposed withdrawal of Tavneos." The fire date is June 29, 2026. Let's search for "Tavneos" OR "avacopan" and "ADVOCATE" OR "Amgen" OR "Duke Clinical Research Institute" OR "DCRI" FDA.

Wow, this is a massive, highly consequential development! Let's review: - Today (June 26, 2026), the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended revoking the marketing authorization for Amgen's Tavneos (avacopan). - This is due to serious concerns over data integrity and good clinical practice (GCP) violations in the pivotal ADVOCATE trial, which supported the drug's approval. The EMA stated that the pivotal study was conducted in breach of GCP and the trial data is unreliable. - This comes just as Amgen is preparing to defend Tavneos in the US. The FDA formally began withdrawal proceedings in April 2026, and Amgen requested a public hearing and commissioned the Duke Clinical Research Institute (DCRI) to do an independent re-evaluation of the ADVOCATE trial data. - The FDA public comment period and Amgen's submission are due around June 29, 2026. This CHMP recommendation to revoke European marketing authorization is a massive blow to Amgen and a major escalation. Let's fetch `https://www.fiercepharma.com/pharma/chmp-reverses-marketing-recommendation-amgens-tavneos-fda-hearing-looms` to get the full details. This is an incredible find and directly addresses the watch thread `019ec855-5381-7936-a3b6-a40d207e679d`. Let's fetch it.

This is an incredibly rich, detailed article that provides a massive update on multiple fronts: 1. Tavneos (avacopan): The CHMP has formally recommended revoking the marketing authorization for Amgen/CSL's Tavneos in the EU. This is based on the determination that the main Advocate study was "conducted in breach of good clinical practice (GCP) principles," and the data provided "were found to be incorrect and misleading and could no longer be relied upon for demonstrating Tavneos’ effectiveness." 2. In the US, the deadline for Amgen's hearing submission has been extended by one month to July 29, 2026. This is a crucial update on the watch thread `019ec855-5381-7936-a3b6-a40d207e679d`. 3. CHMP also handed out negative opinions to: - MaaT Pharma's MaaT013 (Xervyteg) for acute Graft-versus-Host disease (aGvHD). - Netherlands Cancer Institute's Tacquell in advanced melanoma. - Omeros's Yartemlea (narsoplimab) for hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). (This relates to watch thread `019ef183-efef-70f6-9f55-cbbd11c943bb` / Omeros press release on European MAA update for narsoplimab in TA-TMA). 4. Positive recommendations from CHMP: - Eli Lilly's Jaypirca (pirtobrutinib) for chronic lymphocytic leukemia (CLL) across all lines of therapy. - Incyte's Opzelura (ruxolitinib) cream for moderate atopic dermatitis. - Acadia Pharmaceuticals' Daybu (trofinetide) for Rett syndrome, which reversed a previous negative opinion after a re-examination. Let's do some more searches to see if there are other major clinical trials, outbreaks, space, or energy developments. Let's search for "ISS Zvezda module" to see if there are any updates on the air leaks. And let's search for "H5N1" "vaccine" or "bird flu" vaccine. Let's do a search on "ISS" "Zvezda" OR "leak" first.

This is an extraordinary and vivid story that directly updates the watch thread `019ea447-7d90-733c-acee-2eb6c1313c78` ("ISS Russian Zvezda module air leaks and repairs"). Let's see what happened: - On June 5, 2026, NASA ordered astronauts to shelter in the SpaceX Crew Dragon capsule during a tense standoff over repairs to the leaking Russian Zvezda module's PrK transfer tunnel. - The leak has been a long-standing issue since September 2019, venting nearly 2 kilograms of air a day. - The crisis escalated when Russian cosmonauts proposed using a drill and a saw on the hull to perform structural repairs on the cracks. NASA officials objected to this high-risk method, fearing it would worsen the structural integrity, and instructed their astronauts to take shelter in the Crew Dragon capsule as a precaution. - There is a growing dispute between NASA and Roscosmos on how to proceed. Russia has suggested they may permanently seal the PrK tunnel if the leaks cannot be safely repaired, which would reduce air loss but limit station flexibility. NASA faces a 2027 deadline to decide if the tunnel must be permanently closed. Let's fetch `https://spacenews.com/astronauts-briefly-shelter-in-dragon-during-iss-leak-repair/` or `https://www.nasa.gov/blogs/spacestation/2026/06/05/nasa-provides-update-on-space-station-leak/` to get the technical specifics. Let's fetch the SpaceNews article or the NASA blog post first. Let's try `https://spacenews.com/astronauts-briefly-shelter-in-dragon-during-iss-leak-repair/`.

This is a superb primary source. It describes exactly what happened on June 5, 2026: - NASA instructed the four members of Crew-12 (at the station since February) and NASA astronaut Chris Williams (who flew on Soyuz in November) to shelter in the Crew Dragon spacecraft. - The move was prompted by Roscosmos attempting to repair an air leak in the PrK vestibule of the Zvezda service module. The leak had increased, and Roscosmos pursued a repair effort that NASA deemed risky. - Specifically, the repair was called off after Roscosmos opted not to proceed with the more extensive repairs and instead took measurements and coated one site with sealant. - The air leak in PrK has been monitored for years (since 2019). NASA and Roscosmos have not settled on a root cause and disagree on the severity. NASA is concerned Roscosmos isn't adhering to protocols to lower pressure when not in use. - The hatch separating PrK from the rest of Zvezda is kept closed except when accessing a Progress cargo spacecraft. When open, NASA keeps U.S. astronauts in the U.S. segment and closes the hatch between U.S. and Russian segments. Let's do a search on other active watches. What about the "GondolaBio Phase 2b/3 PATHWAY trial initiation of PORT-77 in EPP" or "MoonLake Phase 3 IZAR-1 trial readout of sonelokimab in psoriatic arthritis"? Let's check the MoonLake Phase 3 IZAR-1 trial. The fire date was set as mid-2026 (August 31, 2026). Let's see if there are any recent updates or if it has read out already. Let's do a search.

Ah, this is a massive clinical trial readout! Let's look at the details: - On June 21, 2026, MoonLake Immunotherapeutics reported final Week 52 (one-year) results from its Phase 3 VELA-1 and VELA-2 trials (the VELA program) evaluating its IL-17A/F nanobody, sonelokimab (SLK), in moderate-to-severe hidradenitis suppurativa (HS). - This is a highly significant milestone that directly relates to the watch thread `019ef183-fc49-7cab-b8ec-f8608d9b8c64` / `019ef183-efef-70f6-9f55-cbbd11c943bb` (MoonLake planned BLA submission for sonelokimab in HS, targeted for late September 2026). - The data showed durable, strong clinical outcomes (HiSCR75 and HiSCR90) through one year, further solidifying the clinical profile of sonelokimab as a potential best-in-class treatment for HS. - Let's fetch the official press release from MoonLake or a detailed news article to get the exact numbers and quotes: `https://www.globenewswire.com/news-release/2026/06/21/3314997/0/en/moonlake-announces-week-52-results-of-sonelokimab-from-its-phase-3-vela-program-in-hidradenitis-suppurativa-and-confirms-investor-day-on-june-22-2026.html` or `https://ir.moonlaketx.com/news-releases/news-release-details/moonlake-announces-week-52-results-sonelokimab-its-phase-3-vela/`. Let's fetch it.

This is a fantastic and extremely detailed primary source that provides a comprehensive update on MoonLake's sonelokimab in HS. Key points: - MoonLake reported Week 52 (one-year) results from its Phase 3 VELA-1 and VELA-2 trials of sonelokimab in adults with moderate-to-severe hidradenitis suppurativa (HS). - Efficacy: ~67.2% of patients treated with SLK achieved HiSCR75 at Week 52. ~33.1% achieved HiSCR100 (complete clearance). ~26.0% achieved IHS4-100 (inflammatory remission). - Quality of life: mean score difference of -15.0 points in HiSQOL, indicating an average change from "severe" to "mild" impairment. Nearly half (46.5%) experienced a marked reduction in pain (>=3-point improvement). - VELA-TEEN trial in adolescent HS patients: ~68% achieved HiSCR75 at Week 24, with ~45% achieving HiSCR100. - Dosing: 120mg Q4W (once every four weeks) subcutaneous. - Regulatory milestones: Submission of the BLA for SLK in HS, including adolescent data, is expected at the end of September 2026. This is an active watch thread `019ef183-efef-70f6-9f55-cbbd11c943bb`. - Also confirms upcoming milestones: - Mid-2026: Primary endpoint readout of the Phase 3 IZAR-1 trial in PsA (psoriatic arthritis) - this is watch thread `019ef184-1ea4-72e1-a12e-ed934bbac64e`. Let's check if there is any other major news in the past few days. Let's do a search on: - "GondolaBio" PORT-77 PATHWAY trial. - "Dianthus" CAPTIVATE or MoMeNtum. - "Belite Bio" tinlarebant FDA acceptance. - Let's search for "H5N1" "bird flu" vaccine clinical trial. Is there any update on Moderna's mRNA-1018 or other bird flu vaccine trials? Let's search for "Moderna" "mRNA-1018" OR "bird flu" "Phase 3". Let's do this search.

Let's look at the news results: "CDC won’t publish report showing COVID-19 vaccine effectiveness; former pharmacy president sentenced in $33M compounded drug kickback scheme; mRNA bird flu vaccine hits late-stage testing – Morning Medical Update" on June 26, 2026. This article seems to have several interesting points. Wait, let's fetch it to see what is mentioned. Let's do a `web_fetch` on `https://www.medicaleconomics.com/view/cdc-won-t-publish-report-showing-covid-19-vaccine-effectiveness-former-pharmacy-president-sentenced-in-33m-compounded-drug-kickback-scheme-mrna-bird-flu-vaccine-hits-late-stage-testing-morning-medical-update`. This looks like a goldmine of recent public health news.

This is a truly phenomenal article! Let's dissect the three major stories and cross-reference them with our prior findings and open threads: 1. **CDC COVID-19 vaccine study blocked by HHS**: - This directly relates to the prior finding `cdc-blocked-covid-vaccine-study-published-jama`. In that finding, we reported on a blocked CDC COVID-19 vaccine study that was eventually published in *JAMA Network Open* amid a scientific integrity dispute. - Wait, let's re-verify the details. This new article says "HHS declined an MMWR manuscript over vaccine-effectiveness methodology... Andrew Nixon, an HHS spokesman, said the manuscript was not accepted due to concerns about the methodological approach... The decision comes under the leadership of HHS Secretary Robert F. Kennedy Jr." - Let's check the date of publication or the details. The article says "The decision comes under the leadership of HHS Secretary Robert F. Kennedy Jr., whose vaccine advisory panel last September scrapped a broad recommendation for COVID shots... Had it been published, the report would have shown that the vaccines reduced emergency department (ED) visits and hospitalizations among healthy adults by approximately half this past winter, as reported by Reuters." - This is a highly relevant update on the ongoing scientific integrity and public health policy clashes under RFK Jr.'s leadership at HHS. 2. **Moderna's H5N1 Bird Flu Vaccine (mRNA-1018) Phase 3 Trial**: - This is directly related to watch thread `019e9f1e-f092-7114-960b-1c3b5c994320` ("Monitor topline safety and immunogenicity readouts from Moderna's Phase 3 trial of mRNA-1018 (enrolling ~4,000 healthy adults in the US and UK).") - The article notes: "Moderna has begun a late-stage trial of its experimental bird flu vaccine, mRNA-1018, enrolling approximately 4,000 healthy adults in the United States and United Kingdom — the first time an mRNA-based pandemic bird flu vaccine has reached this stage of testing. The trial is backed by a $54 million investment from the Coalition for Epidemic Preparedness Innovations (CEPI), which stepped in after HHS Kennedy canceled more than $700 million in U.S. government contracts with Moderna for bird flu vaccine development last May." - Also: "Moderna said it would reserve 20% of its manufacturing capacity for supply to low- and middle-income countries at affordable prices. The company said any regulatory filing for mRNA-1018 would also be supported by data from its seasonal flu vaccine candidate, mRNA-1010, currently under review in the U.S., European Union, Canada, and Australia." - This provides critical context on why CEPI is funding it (and the amount: $54 million) and the 20% capacity reservation. Let's do a search to see if there are any other recent clinical trial readouts, approvals, or public health news. What about Omeros and narsoplimab? The press release from today (June 26) says: "Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA" and that the CHMP issued a negative opinion. Let's do a search on Omeros narsoplimab CHMP.

Let's fetch `https://investor.omeros.com/news/news-details/2026/Omeros-Corporation-Announces-Update-on-European-Marketing-Authorization-Application-for-Narsoplimab-in-TA-TMA/default.aspx` to read the official press release on Omeros. Let's fetch it.

This is another high-impact regulatory update: - On June 26, 2026, Omeros Corporation announced that the CHMP has adopted a negative opinion on the European marketing authorization application (MAA) for narsoplimab (approved in the US in Dec 2025 as Yartemlea) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). - Omeros intends to request a re-examination of the CHMP opinion and seek review by an Ad Hoc Expert Group (AHEG), a panel of external scientific and clinical experts convened by the EMA. - The MAA is supported by clinical data from Omeros' pivotal trial in TA-TMA compared to survival in an external registry, which was the same data that the US FDA used to grant approval. Let's double-check if there are other threads we should address. Let's see if there are any updates on Belite Bio's tinlarebant. The watch thread `019ec855-8c35-71a4-b33b-90db344bf45d` is: "Monitor the FDA's decision to accept Belite Bio's NDA for tinlarebant in Stargardt disease type 1 following the 60-day filing review period, and the assignment of a PDUFA target action date." The fire date is August 11, 2026. This is in the future, so we will keep it open. Let's check if there are any updates on: - uniQure's BLA submission for AMT-130 in Huntington's disease (targeted for Q3 2026). - GondolaBio Phase 2b/3 PATHWAY trial initiation of PORT-77 in EPP (expected Q3 2026). - MoonLake Phase 3 IZAR-1 trial readout of sonelokimab in psoriatic arthritis (expected mid-2026). This is also expected soon. Let's write up our findings. Let's review the findings we have: 1. **The Post-Makary FDA Pivot: Reversals, Resubmissions, and a Return to Advisory Committees (featuring Capricor and Replimune)**: - This represents a highly significant structural shift in FDA regulatory behavior following the high-profile departures of former FDA Commissioner Marty Makary and CBER director Vinay Prasad. - We will tell the story through the specific, concrete developments of Capricor's deramiocel (CAP-1002) for DMD cardiomyopathy and Replimune's RP1 for advanced melanoma. - Capricor's deramiocel, rejected in July 2025 under Prasad, aced its Phase 3 HOPE-3 trial in Dec 2025. Its resubmission was accepted in March 2026 with an August 22, 2026 PDUFA date. On June 26, 2026, the FDA scheduled an advisory committee meeting for July 29, 2026. - Replimune's RP1, rejected twice (July 2025 and April 2026), had its resubmission accepted on June 26, 2026, with an August 2, 2026 PDUFA date and an advisory committee meeting scheduled for late July. - Industry observers note this is a return to a more structured, collaborative "normalcy" and a reliance on public advisory committees (adcomms) rather than unilateral, behind-closed-doors rejections. - Suitable slug: `fda-regulatory-pivot-advisory-committees` or similar. Let's make it `fda-regulatory-pivot-advisory-committees-capricor-replimune`. 2. **Operation Trailblazer: HHS and FDA Formally Roll Out Major Clinical Trial Reforms and Draft Guidances to Counter China**: - This directly refines the existing prior finding `hhs-clinical-trials-reform-operation-trialblazer`. - We will reuse the slug `hhs-clinical-trials-reform-operation-trialblazer` to update it in place. - It will incorporate the concrete details of the June 22, 2026 rollout: - The Expedited Investigational New Drug (IND) pilot program to accelerate drug identification to first-in-human (FIH) Phase 1 trials by 6 to 12 months. - The revised draft guidance "Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products" allowing a single pivotal trial plus confirmatory evidence for drug approval. - The new draft guidance on Quantitative Systems Pharmacology (QSP)-based dose selection to determine MABEL dose, moving away from animal toxicology. - Updated draft guidance on master protocols (basket, umbrella, and platform trials). - Launch of "The Phase 1 IND Navigator" and Chemistry, Manufacturing, and Control (CMC) guidance pages. - The new CDER/CBER Phase 1 call center. 3. **European CHMP Recommends Revoking Amgen's Tavneos (avacopan) Marketing Authorization Over Data Integrity and GCP Breaches**: - This is a massive, dramatic international regulatory event. - On June 26, 2026, the EMA's CHMP recommended revoking the marketing authorization for Amgen's Tavneos (avacopan). - This is due to the determination that the pivotal 331-patient Advocate trial was "conducted in breach of good clinical practice (GCP) principles" and that the trial data "were found to be incorrect and misleading." - This comes as Amgen is preparing to defend Tavneos in the US, where the FDA proposed a formal withdrawal of approval in April 2026. - In the US, the deadline for Amgen's hearing submission has been extended by one month to July 29, 2026. - This directly updates the watch thread `019ec855-5381-7936-a3b6-a40d207e679d`. We will record an event on it and resolve it. Wait, the watch title is "Amgen Tavneos FDA hearing submission and public docket close" and the trigger is "Fires when Amgen submits its evidence and the public docket closes on June 29, 2026." Since the deadline was extended to July 29, 2026, let's keep it open but update the fire date or record an event or record a watch. Actually, let's record an event on the watch thread showing that the deadline was extended to July 29, 2026, and that the CHMP has recommended revoking European authorization, but keep the watch open since the final US hearing submission is now July 29, 2026. - Let's name the slug `amgen-tavneos-chmp-revocation-data-integrity` or similar. 4. **MoonLake's Sonelokimab Delivers Outstanding Week 52 Phase 3 VELA Results in Hidradenitis Suppurativa, De-risking September BLA Filing**: - On June 21, 2026, MoonLake Immunotherapeutics announced final one-year (Week 52) data from its Phase 3 VELA-1 and VELA-2 trials of sonelokimab in moderate-to-severe HS. - The results showed high, durable efficacy: ~67.2% achieved HiSCR75 and ~33.1% achieved HiSCR100. - Substantial improvements in patient quality of life and pain were reported, showing a potential best-in-class clinical profile. - VELA-TEEN trial in adolescents showed ~68% achieved HiSCR75 at Week 24. - MoonLake confirmed plans to submit its BLA to the FDA by late September 2026, de-risked by these robust results. - Let's name the slug `moonlake-sonelokimab-phase-3-vela-hidradenitis-suppurativa`. 5. **AstraZeneca and Daiichi Sankyo's Datroway (Dato-DXd) Earns CHMP Recommendation for First-Line Metastatic Triple-Negative Breast Cancer**: - On June 26, 2026, the EMA's CHMP issued a positive opinion recommending approval of Datroway (datopotamab deruxtecan) as a first-line monotherapy for patients with unresectable or metastatic TNBC who are not candidates for immunotherapy. - Based on the Phase III TROPION-Breast02 trial, which showed an unprecedented 5.0-month improvement in median overall survival (OS) compared to chemotherapy (23.7 months vs 18.7 months, HR 0.79, p=0.0291) and a 43% reduction in risk of disease progression or death (HR 0.57, p<0.0001). - Datroway was already approved in the US in May 2026. - Let's name the slug `astrazeneca-daiichi-sankyo-datroway-chmp-recommendation-tnbc`. 6. **ISS Crew Shelters in Dragon Capsule Amid Tense Standoff Over Risky Russian Module Repairs**: - On June 5, 2026, NASA ordered five astronauts on the ISS to take shelter inside the SpaceX Crew Dragon capsule due to a high-risk repair attempt proposed by Roscosmos. - The issue involves the long-running air leak in the Russian Zvezda service module's PrK transfer tunnel, which has been venting air since 2019. - When Roscosmos proposed performing extensive, potentially risky structural repairs on the cracks, NASA instructed U.S. segment astronauts to assume an elevated safety posture in the Crew Dragon capsule. - The repairs were ultimately paused, but the dispute highlights ongoing, unresolved technical and safety disagreements between NASA and Roscosmos over the station's aging infrastructure. - Let's name the slug `iss-zvezda-module-air-leaks-dragon-shelter`. Let's double-check if there are other findings. What about Omeros narsoplimab? - On June 26, 2026, Omeros Corporation announced that the CHMP has adopted a negative opinion on the European marketing authorization application (MAA) for narsoplimab (approved in the US in Dec 2025 as Yartemlea) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). - Omeros intends to request re-examination. - This is a very interesting oncology/hematology supportive care update. We can include this as part of our findings or as its own note. Let's make it its own note or a section, but wait! The rule says: "ONE note per theme, never a combined write-up. A finding TELLS THE STORY THROUGH CONCRETE EVIDENCE — it does not just describe the vibe." So we should write separate, high-quality notes for these distinct stories. - Let's write a note for Omeros: `omeros-narsoplimab-chmp-negative-opinion-ta-tma`. Wait, let's look at the HHS blocks CDC vaccine study. - This is an update on the ongoing scientific integrity and public health policy clashes under RFK Jr.'s leadership at HHS. - We have the prior finding `cdc-blocked-covid-vaccine-study-published-jama`. - Let's reuse the slug `cdc-blocked-covid-vaccine-study-published-jama` to update it in place with the latest news that HHS blocked another report in the MMWR showing COVID-19 vaccine effectiveness (showing vaccines reduced ED visits and hospitalizations by half last winter), citing "methodological approach" concerns under RFK Jr.'s leadership. This is a highly relevant, timely update! Let's write these notes. Let's first write the update for `hhs-clinical-trials-reform-operation-trialblazer`. Let's re-read the prior finding description or content. The description says: "On June 22, 2026, the U.S. Department of Health and Human Services (HHS), led by Secretary Robert F. Kennedy, Jr., in coordination with the FDA and NIH, formally launched **Operation Trailblazer**…" Let's drafting the note for `hhs-clinical-trials-reform-operation-trialblazer` first. I will use the `write_note` tool. I will make sure it has a title as the first `# ` heading, is structured with concrete quotes and links, and has a `## Sources` block. No YAML frontmatter. Wait, let's write the note for `hhs-clinical-trials-reform-operation-trialblazer`. Let's construct the body. Let

I will now write the updated note for **Operation Trailblazer** clinical trial reforms, incorporating the specific regulatory actions, pilot program details, and draft guidances released by the HHS and FDA.

I will now write a new note detailing the **post-Makary FDA regulatory pivot**, focusing on the resubmission acceptances and scheduled advisory committee meetings for Capricor's deramiocel and Replimune's RP1. This highlights a broader trend toward collaborative regulatory pathways and public panels following a period of high-profile unilateral rejections.

I will now write a new note detailing the **European CHMP's recommendation to revoke Amgen's Tavneos (avacopan) marketing authorization** due to good clinical practice (GCP) breaches and data integrity issues in the pivotal ADVOCATE study. This is an extremely major international regulatory development.

I will now write a new note detailing **MoonLake's outstanding Week 52 Phase 3 VELA results for sonelokimab in hidradenitis suppurativa**, which paves the way for their planned BLA submission in September 2026. This is a major clinical trial readout.

I will now write a new note detailing **AstraZeneca and Daiichi Sankyo's Datroway (datopotamab deruxtecan; Dato-DXd) earning a positive CHMP recommendation** in the EU for first-line metastatic triple-negative breast cancer (TNBC). This is a major regulatory milestone for an antibody-drug conjugate (ADC).

I will now write a new note detailing the **ISS air leaks and the June 5, 2026 emergency shelter order** where NASA astronauts sheltered in the SpaceX Crew Dragon capsule due to a high-risk repair dispute with Roscosmos. This is a major space and engineering development.

I will now write a new note detailing **Omeros's narsoplimab (Yartemlea) receiving a negative CHMP opinion** in Europe for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), despite its 2025 FDA approval, and Omeros's plans to seek a re-examination. This is a highly relevant clinical and regulatory development.

I will now update the existing note `cdc-blocked-covid-vaccine-study-published-jama` to reflect the latest development regarding HHS's decision to block another CDC report in the MMWR showing COVID-19 vaccine effectiveness. This highlights the ongoing scientific integrity and public health policy clashes under RFK Jr.'s leadership at HHS.

I will now record an event on the watch thread `019ec855-5381-7936-a3b6-a40d207e679d` ("Amgen Tavneos FDA hearing submission and public docket close"). The event is that the FDA has granted Amgen a one-month extension for its formal hearing submission, pushing the deadline to July 29, 2026. This is a crucial update. I will set `resolves: false` since the watch is still ongoing and will now fire on July 29, 2026.

I will now record a new watch for the upcoming **FDA advisory committee meeting for Capricor's deramiocel** on July 29, 2026. This is a crucial dated catalyst.

I will now record a new watch for the **FDA advisory committee meeting for Replimune's RP1 in advanced melanoma**, expected in late July 2026, ahead of its August 2, 2026 PDUFA date. This is a crucial dated catalyst.

I will now record a new watch for the **European Commission's final decision on Omeros's narsoplimab (Yartemlea) re-examination** following the negative CHMP opinion. This is a crucial live process watch.

I will now call `finish_cycle` to complete this research cycle, as all notes are written, events are recorded, and watches have been set.

I have completed the research cycle for topic `019e92c9-9dac-7a47-a1f2-f8f4037c94f9`. ### Summary of Key Findings from this Cycle: 1. **The Post-Makary FDA Pivot ([[fda-regulatory-pivot-advisory-committees-capricor-replimune]])**: In a major shift following the departures of former Commissioner Marty Makary and CBER Director Vinay Prasad, the FDA is showing signs of a collaborative, public-facing regulatory pivot. On June 26, 2026, the FDA accepted Replimune's third BLA resubmission for RP1 in advanced melanoma (PDUFA: August 2, 2026) and scheduled an advisory committee (adcomm) meeting for late July. Concurrently, the FDA scheduled a surprise adcomm on July 29, 2026, for Capricor's deramiocel (CAP-1002) in DMD cardiomyopathy. 2. **Operation Trailblazer Clinical Trial Reforms ([[hhs-clinical-trials-reform-operation-trialblazer]])**: Updated the existing note to detail the formal June 22, 2026 launch of Operation Trailblazer by HHS Secretary Robert F. Kennedy, Jr. Key actions include the FDA's new Expedited IND pilot program to speed up first-in-human Phase 1 trials by 6–12 months, and a revised draft guidance establishing that a single high-quality pivotal trial plus confirmatory evidence is sufficient for drug approval. 3. **European CHMP Recommends Revoking Amgen's Tavneos ([[amgen-tavneos-chmp-revocation-data-integrity]])**: In a massive blow to Amgen, Europe's CHMP recommended revoking the marketing authorization of Tavneos (avacopan) on June 26, 2026. The committee concluded that the pivotal ADVOCATE study was conducted in breach of Good Clinical Practice (GCP) principles and contained "incorrect and misleading" data. This comes as Amgen prepares to defend Tavneos in the US, where the FDA has granted a one-month extension for its formal hearing submission, now due July 29, 2026. 4. **MoonLake's Sonelokimab Phase 3 VELA Results ([[moonlake-sonelokimab-phase-3-vela-hidradenitis-suppurativa]])**: On June 21, 2026, MoonLake reported highly positive final Week 52 (one-year) results from its Phase 3 VELA-1 and VELA-2 trials of sonelokimab in moderate-to-severe hidradenitis suppurativa (HS). The data showed a robust 67.2% HiSCR75 rate and 33.1% HiSCR100 rate, de-risking its planned BLA submission scheduled for late September 2026. 5. **AstraZeneca and Daiichi Sankyo's Datroway CHMP Recommendation ([[astrazeneca-daiichi-sankyo-datroway-chmp-recommendation-tnbc]])**: On June 26, 2026, Datroway (datopotamab deruxtecan; Dato-DXd) earned a positive CHMP opinion in the EU as a first-line monotherapy for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for immunotherapy, backed by a 5.0-month overall survival benefit in the TROPION-Breast02 Phase III trial. 6. **ISS Crew Shelters in Dragon Capsule Amid Repair Standoff ([[iss-zvezda-module-air-leaks-dragon-shelter]])**: On June 5, 2026, NASA ordered five astronauts on the ISS to take shelter inside the SpaceX Crew Dragon capsule due to a high-risk repair attempt proposed by Roscosmos. The dispute involved Roscosmos's proposal to drill and saw into the hull of the leaking Russian Zvezda service module's PrK transfer tunnel, which has been venting air since 2019. 7. **Omeros's Narsoplimab (Yartemlea) Receives Negative CHMP Opinion ([[omeros-narsoplimab-chmp-negative-opinion-ta-tma]])**: On June 26, 2026, Omeros announced that the CHMP adopted a negative opinion on its MAA for narsoplimab in TA-TMA, despite its December 2025 FDA approval, leading Omeros to request a formal re-examination and review by an Ad Hoc Expert Group (AHEG). 8. **Blocked CDC COVID-19 Vaccine Study MMWR Update ([[cdc-blocked-covid-vaccine-study-published-jama]])**: Updated the existing note to reflect that HHS declined an MMWR manuscript showing that COVID-19 vaccines halved ED visits and hospitalizations last winter, citing "methodological approach" concerns under HHS Secretary RFK Jr.'s leadership. ### Recorded Events and Watches: - **Event Recorded:** Updated the Tavneos watch thread (`019ec855-5381-7936-a3b6-a40d207e679d`) to reflect the FDA's one-month extension for Amgen's hearing submission (now due July 29, 2026) and the CHMP's European revocation recommendation. - **New Watch Registered:** FDA advisory committee meeting for Capricor's deramiocel in DMD cardiomyopathy on July 29, 2026. - **New Watch Registered:** FDA advisory committee meeting and PDUFA date (August 2, 2026) for Replimune's RP1 in advanced melanoma. - **New Watch Registered:** EMA re-examination and AHEG review outcome for Omeros's narsoplimab (Yartemlea) in TA-TMA.